Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration

Chowdhury S. Abdullah, Shafiul Alam, Richa Aishwarya, Sumitra Miriyala, Mohammad Alfrad Nobel Bhuiyan, Manikandan Panchatcharam, Christopher B. Pattillo, A. Wayne Orr, Junichi Sadoshima, Joseph A Hill, Md Shenuarin Bhuiyan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular dysfunction, and also induce late-onset cardiomyopathy and heart failure. Despite extensive studies, the pathogenic sequelae leading to the progression of Dox-associated cardiomyopathy remains unknown. We assessed temporal changes in autophagy, mitochondrial dynamics, and bioenergetics in mouse models of acute and chronic Dox-cardiomyopathy. Time course study of acute Dox-treatment showed accumulation of LC3B II in heart lysates. Autophagy flux assays confirmed that the Dox-induced accumulation of autophagosomes occurs due to blockage of the lysosomal degradation process. Dox-induced autophagosomes and autolysosome accumulation were confirmed in vivo by using GFP-LC3 and mRFP-GFP-LC3 transgenic (Tg) mice. Mitochondria isolated from acute Dox-treated hearts showed significant suppression of oxygen consumption rate (OCR). Chronic Dox-cardiotoxicity also exhibited time-dependent accumulation of LC3B II levels and increased accumulation of green puncta in GFP-LC3 Tg hearts. Mitochondria isolated from chronic Dox-treated hearts also showed significant suppression of mitochondrial OCR. The in vivo impairment of autophagic degradation process and mitochondrial dysfunction data were confirmed in vitro using cultured neonatal cardiomyocytes. Both acute and chronic Dox-associated cardiomyopathy involves a multifocal disease process resulting from autophagosomes and autolysosomes accumulation, altered expression of mitochondrial dynamics and oxidative phosphorylation regulatory proteins, and mitochondrial respiratory dysfunction.

Original languageEnglish (US)
Article number2002
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Cardiomyopathies
Doxorubicin
Respiration
Mitochondrial Dynamics
Autophagy
Oxygen Consumption
Mitochondria
Ventricular Dysfunction
Mitochondrial Proteins
Oxidative Phosphorylation
Cardiac Myocytes
Energy Metabolism
Transgenic Mice
Heart Failure

ASJC Scopus subject areas

  • General

Cite this

Abdullah, C. S., Alam, S., Aishwarya, R., Miriyala, S., Bhuiyan, M. A. N., Panchatcharam, M., ... Bhuiyan, M. S. (2019). Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Scientific Reports, 9(1), [2002]. https://doi.org/10.1038/s41598-018-37862-3

Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. / Abdullah, Chowdhury S.; Alam, Shafiul; Aishwarya, Richa; Miriyala, Sumitra; Bhuiyan, Mohammad Alfrad Nobel; Panchatcharam, Manikandan; Pattillo, Christopher B.; Orr, A. Wayne; Sadoshima, Junichi; Hill, Joseph A; Bhuiyan, Md Shenuarin.

In: Scientific Reports, Vol. 9, No. 1, 2002, 01.12.2019.

Research output: Contribution to journalArticle

Abdullah, CS, Alam, S, Aishwarya, R, Miriyala, S, Bhuiyan, MAN, Panchatcharam, M, Pattillo, CB, Orr, AW, Sadoshima, J, Hill, JA & Bhuiyan, MS 2019, 'Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration', Scientific Reports, vol. 9, no. 1, 2002. https://doi.org/10.1038/s41598-018-37862-3
Abdullah, Chowdhury S. ; Alam, Shafiul ; Aishwarya, Richa ; Miriyala, Sumitra ; Bhuiyan, Mohammad Alfrad Nobel ; Panchatcharam, Manikandan ; Pattillo, Christopher B. ; Orr, A. Wayne ; Sadoshima, Junichi ; Hill, Joseph A ; Bhuiyan, Md Shenuarin. / Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{98f9166b260a469b850c5fc71be1ed9e,
title = "Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration",
abstract = "Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular dysfunction, and also induce late-onset cardiomyopathy and heart failure. Despite extensive studies, the pathogenic sequelae leading to the progression of Dox-associated cardiomyopathy remains unknown. We assessed temporal changes in autophagy, mitochondrial dynamics, and bioenergetics in mouse models of acute and chronic Dox-cardiomyopathy. Time course study of acute Dox-treatment showed accumulation of LC3B II in heart lysates. Autophagy flux assays confirmed that the Dox-induced accumulation of autophagosomes occurs due to blockage of the lysosomal degradation process. Dox-induced autophagosomes and autolysosome accumulation were confirmed in vivo by using GFP-LC3 and mRFP-GFP-LC3 transgenic (Tg) mice. Mitochondria isolated from acute Dox-treated hearts showed significant suppression of oxygen consumption rate (OCR). Chronic Dox-cardiotoxicity also exhibited time-dependent accumulation of LC3B II levels and increased accumulation of green puncta in GFP-LC3 Tg hearts. Mitochondria isolated from chronic Dox-treated hearts also showed significant suppression of mitochondrial OCR. The in vivo impairment of autophagic degradation process and mitochondrial dysfunction data were confirmed in vitro using cultured neonatal cardiomyocytes. Both acute and chronic Dox-associated cardiomyopathy involves a multifocal disease process resulting from autophagosomes and autolysosomes accumulation, altered expression of mitochondrial dynamics and oxidative phosphorylation regulatory proteins, and mitochondrial respiratory dysfunction.",
author = "Abdullah, {Chowdhury S.} and Shafiul Alam and Richa Aishwarya and Sumitra Miriyala and Bhuiyan, {Mohammad Alfrad Nobel} and Manikandan Panchatcharam and Pattillo, {Christopher B.} and Orr, {A. Wayne} and Junichi Sadoshima and Hill, {Joseph A} and Bhuiyan, {Md Shenuarin}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-37862-3",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration

AU - Abdullah, Chowdhury S.

AU - Alam, Shafiul

AU - Aishwarya, Richa

AU - Miriyala, Sumitra

AU - Bhuiyan, Mohammad Alfrad Nobel

AU - Panchatcharam, Manikandan

AU - Pattillo, Christopher B.

AU - Orr, A. Wayne

AU - Sadoshima, Junichi

AU - Hill, Joseph A

AU - Bhuiyan, Md Shenuarin

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular dysfunction, and also induce late-onset cardiomyopathy and heart failure. Despite extensive studies, the pathogenic sequelae leading to the progression of Dox-associated cardiomyopathy remains unknown. We assessed temporal changes in autophagy, mitochondrial dynamics, and bioenergetics in mouse models of acute and chronic Dox-cardiomyopathy. Time course study of acute Dox-treatment showed accumulation of LC3B II in heart lysates. Autophagy flux assays confirmed that the Dox-induced accumulation of autophagosomes occurs due to blockage of the lysosomal degradation process. Dox-induced autophagosomes and autolysosome accumulation were confirmed in vivo by using GFP-LC3 and mRFP-GFP-LC3 transgenic (Tg) mice. Mitochondria isolated from acute Dox-treated hearts showed significant suppression of oxygen consumption rate (OCR). Chronic Dox-cardiotoxicity also exhibited time-dependent accumulation of LC3B II levels and increased accumulation of green puncta in GFP-LC3 Tg hearts. Mitochondria isolated from chronic Dox-treated hearts also showed significant suppression of mitochondrial OCR. The in vivo impairment of autophagic degradation process and mitochondrial dysfunction data were confirmed in vitro using cultured neonatal cardiomyocytes. Both acute and chronic Dox-associated cardiomyopathy involves a multifocal disease process resulting from autophagosomes and autolysosomes accumulation, altered expression of mitochondrial dynamics and oxidative phosphorylation regulatory proteins, and mitochondrial respiratory dysfunction.

AB - Doxorubicin (Dox) is a highly effective anticancer drug but cause acute ventricular dysfunction, and also induce late-onset cardiomyopathy and heart failure. Despite extensive studies, the pathogenic sequelae leading to the progression of Dox-associated cardiomyopathy remains unknown. We assessed temporal changes in autophagy, mitochondrial dynamics, and bioenergetics in mouse models of acute and chronic Dox-cardiomyopathy. Time course study of acute Dox-treatment showed accumulation of LC3B II in heart lysates. Autophagy flux assays confirmed that the Dox-induced accumulation of autophagosomes occurs due to blockage of the lysosomal degradation process. Dox-induced autophagosomes and autolysosome accumulation were confirmed in vivo by using GFP-LC3 and mRFP-GFP-LC3 transgenic (Tg) mice. Mitochondria isolated from acute Dox-treated hearts showed significant suppression of oxygen consumption rate (OCR). Chronic Dox-cardiotoxicity also exhibited time-dependent accumulation of LC3B II levels and increased accumulation of green puncta in GFP-LC3 Tg hearts. Mitochondria isolated from chronic Dox-treated hearts also showed significant suppression of mitochondrial OCR. The in vivo impairment of autophagic degradation process and mitochondrial dysfunction data were confirmed in vitro using cultured neonatal cardiomyocytes. Both acute and chronic Dox-associated cardiomyopathy involves a multifocal disease process resulting from autophagosomes and autolysosomes accumulation, altered expression of mitochondrial dynamics and oxidative phosphorylation regulatory proteins, and mitochondrial respiratory dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=85061563251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061563251&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-37862-3

DO - 10.1038/s41598-018-37862-3

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2002

ER -